At the request of the FDA, Bayer Pharmaceuticals Corp. has agreed to stop marketing Trasylol. Trasylol is a drug that controls bleeding during heart surgery. According to recent studies, using Trasylol over other similar drugs significantly increases the risk of death, kidney failure, stroke or heart problems. The FDA is waiting for the results from a new study being conducted in Canada to determine if stronger measures should be taken. To read more about this topic, visit trasylol marketing
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.